LONDON, UK, 11 September, 2014 - Skyepharma PLC (LSE SKP), the expert oral and inhalation drug delivery company, announces that it will be presenting at the Innovation in Respiratory Diseases event being held today, Thursday 11 September (10.00 – 15.00), at FTI Consulting, 200 Aldersgate, Aldersgate Street, London, EC1A 4HD.
Skyepharma’s Executive Vice President Pharmaceutical Development, Dr Geraldine Venthoye, and Executive Vice President Medicinal & Regulatory Development, Dr Kirsten Kaiser, together with University Hospital of South Manchester Professor of Clinical Pharmacology and Respiratory Medicine, Professor Dave Singh, are scheduled to present on the topic: “Addressing unmet needs in COPD” at 13.15 BST. A copy of the presentation slides is available on the Investor Relations section of the Skyepharma website.
The Innovation in Respiratory Diseases event will include presentations and discussion on the current challenges and advancements in the treatment of respiratory diseases.
For further information please contact:
Skyepharma PLC
Peter Grant, Chief Executive Officer
Andrew Derodra, Chief Financial Officer
+44 207 881 0524
Jonathan Birt, Investor and Media Relations
+44 7860 361746
FTI Consulting
Julia Phillips/Rob Winder/Natalie Garland-Collins
+44 203 727 1000
N+1 Singer Shaun Dobson/Gillian Martin +44 207 496 3000
About Skyepharma
Skyepharma combines proven scientific expertise with validated proprietary drug delivery technologies to develop innovative oral and inhalation pharmaceutical products. The Group is eligible for revenues from 16 approved products in the areas of inhalation, oral, topical and injectable drug delivery as well as generating income from the development of further products and technology licenses. The products developed by the Group are marketed throughout the world by big pharma as well as speciality pharmaceutical companies. For more information, visit www.skyepharma.com.
Help employers find you! Check out all the jobs and post your resume.
